-

Cardiac Insight’s Cardea 20/20 ECG™ System Utilized by the United States Coast Guard Auxiliary in Conjunction With the USCG Academy Medical Clinic to Screen Newly Recruited USCG Academy Cadets for Risk of Sudden Cardiac Death (SCD)

BELLEVUE, Wash.--(BUSINESS WIRE)--Sudden Cardiac Arrest (SCA) is the leading medical cause of death in young athletes during sport. The presence of congenital abnormalities and electrical abnormalities within the heart that cause SCA can be detected by performing a simple, noninvasive 12-lead ‘ECG’ test or electrocardiogram. The United States Coast Guard Auxiliary (USCGAUX) Health Services and USCG Academy has recognized the importance of screening for possible SCA and has supported this initiative by performing their first ECG screenings on their latest group of USCG swabs (first year cadets).

During the week of July 5th, 2021, volunteers from the USCG Auxiliary teamed with cardiologists from the USCG Auxiliary Health Services and USCG Academy Clinic in collaboration with the Cardiology division of the Uniformed Services University of the Health Sciences to perform ECG screenings on 293 of the Coast Guard’s newest cadets. This joint effort was the first venture of its type at the Coast Guard Academy as they took extra strides to ensure the health of their patient population.

Over several days, hundreds of USCG swabs were screened by performing an ECG with the Cardea 20/20 ECG™ System manufactured by Cardiac Insight. The Cardea 20/20 ECG System is equipped with the International Recommendations for ECG Interpretation in Athletes1 which is more accurate at discerning the specifics of a young athlete’s cardiac anatomy and detecting any abnormalities that need further evaluation by a physician.

“ECG screening of these cadet student athletes with the Cardea 20/20 ECG provided immediate and extremely reliable cardiac ECG data to help prevent a future sudden cardiac event,” remarked James McCriskin, DO, FACP, FACC.

To learn more about the rationale and benefits of ECG testing in athletes, including for ‘tactical’ or occupational athletes in the armed services, see the USCG press release: https://www.mycg.uscg.mil/News/Article/2708271/perfect-cadence-the-us-coast-guard-academys-new-electrocardiogram-initiative/

About Cardiac Insight: Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a U.S. developer of advanced body-worn digital health care information devices for cardiology, respiratory and other complex disease states. The company’s technologies and systems are created using advanced algorithms and software that provide improvements in mean time to diagnosis. Cardiac Insight’s mission is to invent complete and progressive solutions for unmet clinical needs on behalf of physicians, patients, and payers. Cardiac Insight was founded in 2008 and is based in Bellevue, WA.

References

1 Sharma S1, Drezner JA, Baggish A., International Recommendations for Electrocardiographic Interpretation in Athletes, J Am Coll Cardiol. 2017 Feb 28;69(8):1057-1075.

Contacts

Ann Demaree
media@cardiacinsightinc.com
206-596-2073

Cardiac Insight

Details
Headquarters: Bellevue, Washington
CEO: Min Kim
Employees: 33
Organization: PRI

Release Versions

Contacts

Ann Demaree
media@cardiacinsightinc.com
206-596-2073

Social Media Profiles
More News From Cardiac Insight

Cardiac Insight’s Cardea SOLO™ Wearable ECG System Chosen for Stanford Medicine Study to Measure Atrial Fibrillation in Older Women

BELLEVUE, Wash.--(BUSINESS WIRE)--Cardiac Insight, Inc., a leading healthcare innovator specializing in prescription-based wearable cardiac sensors and automated electrocardiogram (ECG) analysis software for cardiac arrhythmia diagnosis, today announced that researchers at Stanford Medicine selected the company’s Cardea SOLO™ wearable ECG system for a medical study entitled: Serial 7-Day Electrocardiogram Patch Screening for Atrial Fibrillation in High-Risk Older Women by the CHARGE-AF Score Th...

Cardiac Insight Comments on CMS Announcement of National Payment Rates for Long-Term Continuous ECG (LT-ECG) Monitoring in 2023

BELLEVUE, Wash.--(BUSINESS WIRE)--Cardiac Insight, Inc., creators of Cardea SOLO™ prescription cardiac sensors and automated electrocardiography (ECG) Analysis Software, shares its perspective on the latest CMS ruling, which provides nationwide physician confidence in receiving the appropriate reimbursement for prescribing LT-ECG (Long Term ECG) ambulatory diagnostic testing. The new Medicare Physician Fee Schedule (MPFS) rule establishes national Medicare and Medicaid payment rates for ambulat...

Cardiac Insight’s Cardea SOLO™ ECG System Named as Finalist in Fierce Innovation Awards Healthcare Edition

BELLEVUE, Wash.--(BUSINESS WIRE)--Cardiac Insight, Inc., a leading healthcare innovator specializing in prescription-based wearable cardiac sensors and automated electrocardiogram (ECG) analysis software for cardiac arrhythmia diagnosis, has been named a finalist in the 2022 Fierce Healthcare Innovation Awards for its Cardea SOLO™ ECG System. The awards recognize innovations that are transforming the healthcare industry. Cardiac Insight’s Cardea SOLO ECG system was selected by a panel of expert...
Back to Newsroom